Stifel Maintains Buy on Disc Medicine, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Buy rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $40 to $50.
June 09, 2023 | 5:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst maintains Buy rating on Disc Medicine (NASDAQ:IRON) and raises price target from $40 to $50.
The news of Stifel maintaining a Buy rating and raising the price target for Disc Medicine (NASDAQ:IRON) from $40 to $50 indicates a positive outlook for the company's stock. This could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100